NCT05217901View on ClinicalTrials.gov

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

April 30, 2022

Study Completion Date

May 9, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

14C-labeled ASP0367

Oral

Trial Locations (1)

53704

Labcorp CRU, Madison

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY